The role of TRAIL in bone marrow transplantation
TRAIL在骨髓移植中的作用
基本信息
- 批准号:6434853
- 负责人:
- 金额:$ 35.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-07-01 至 2006-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adenoviridae apoptosis bone marrow transplantation cell line cytokine receptors cytolysins cytotoxic T lymphocyte endotoxins flow cytometry gene expression genetically modified animals graft versus host disease helper T lymphocyte histocompatibility antigens homologous transplantation interferons interleukin 1 interleukin 12 laboratory mouse leukocyte activation /transformation ligands macrophage neutralizing antibody pore forming protein protein structure function transfection /expression vector tumor necrosis factor alpha
项目摘要
DESCRIPTION (provided by applicant): The donor T cell plays a pivotal role in
allogeneic bone marrow transplantation (BMT). Cytotoxic T cells of donor origin
are primarily responsible for graft-versus-tumor (GVT) activity and
graft-versus-host-disease (GVHD). Cytotoxic T cells can exert their cytolytic
activity through at least two effector pathways: Fas ligand (FasL) and
perforin/granzyme. These two cytotoxic effector pathways, in addition to TNF
(which has been proposed as a third T cell effector pathway), play an important
role in the development of GVHD and GVT. Recent studies in murine models by us
and others have demonstrated a differential use of these cytolytic pathways by
donor T cells in GVHD, GVT and donor leukocyte infusion (DLI). This suggests
that the selective inhibition of a cytolytic pathway could represent a novel
strategy for the separation of GVT from GVHD. Tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily, which
includes FasL and TNF. TRAIL has been shown to induce apoptosis of tumor cells
without affecting nontransformed cells, however its role in health and disease
is still largely unknown. We propose in this application to dissect the role of
TRAIL in GVHD, GVT, and donor engraftment y using recently generated
TRAIL-deficient mice and neutralizing anti-TRAIL antibodies in clinically
relevant murine BMT models. In Specific Aim 1 we propose to study the effects
of a) TRAIL-deficient B6 (B6.TRAIL-/-) donor cells, or b) in vivo
administration of a neutralizing anti-TRAIL antibody on GVHD morbidity and
mortality and specific GVHD-associated organ pathology. We will study the role
of TRAIL in the pathophysiology of GVHD in the recipients by analysis of donor
T cell expansion and activity, CD4/8 ratio, serum cytokine levels (IL-1, IL-12,
TNF, IFN), serum endotoxin levels, and macrophage activation. This analysis
will be repeated with recipients which either a) have received sublethal
irradiation to determine graft rejection, or b) have been inoculated with tumor
cells at the time of BMT to analyze the importance of the TRAIL pathway for GVT
(and DLI) in relation to GVHD. In Specific Aim 2 we will study the effects of
TRAIL-deficiency in the recipient and its effects on the development of GVHD.
In Specific Aim 3 we propose to generate mice with multiple deficiencies in the
cytolytic pathways. These mice will be used for similar experiments as
described in Aims 1 and 2 to discover any redundancy, synergy or antagonism of
these cytolytic pathways in GVHD, GVT, and engraftment. Finally, in Specific
Aim 4 we propose to enhance GVT activity through the overexpression of TRAIL
(by adenovirus-mediated delivery) in donor T cells. These studies could provide
a better mechanistic understanding of the role of the TRAIL pathway in (a) T
cell cytotoxicity in vivo, and (b) GVHD, GVT and engraftment after BMT, which
could have immediate clinical applicability.
描述(由申请人提供):供体T细胞在以下方面发挥关键作用:
异基因骨髓移植(BMT)。供体来源的细胞毒性T细胞
主要负责移植物抗肿瘤(GVT)活性,
移植物抗宿主病(GVHD)。细胞毒性T细胞可以发挥其细胞溶解作用,
通过至少两种效应物途径的活性:Fas配体(FasL)和
穿孔素/颗粒酶。这两种细胞毒性效应物途径,除了TNF
(已被提出作为第三个T细胞效应途径),发挥重要作用,
在GVHD和GVT的发展中的作用。我们在小鼠模型中的最新研究
和其他人已经证明了这些细胞溶解途径的不同用途,
GVHD、GVT和供体白细胞输注(DLI)中的供体T细胞。这表明
细胞溶解途径的选择性抑制可能代表了一种新的
将GVT与GVHD分开的策略。肿瘤坏死因子相关
细胞凋亡诱导配体(TRAIL)是肿瘤坏死因子超家族的成员,
包括FasL和TNF。TRAIL已被证明可诱导肿瘤细胞凋亡
而不影响非转化细胞,然而它在健康和疾病中的作用
仍是未知数在本申请中,我们提出剖析
TRAIL在GVHD、GVT和供体移植中的应用
TRAIL缺陷型小鼠和临床中的中和性抗TRAIL抗体
相关鼠BMT模型。在具体目标1中,我们建议研究
a)TRAIL缺陷型B6(B6.TRAIL-/-)供体细胞,或B)体内
施用中和性抗TRAIL抗体对GVHD发病率的影响,
死亡率和特异性GVHD相关器官病理学。我们将研究
TRAIL在受者GVHD病理生理中的作用
T细胞扩增和活性、CD 4/8比率、血清细胞因子水平(IL-1、IL-12、
TNF、IFN)、血清内毒素水平和巨噬细胞活化。该分析
将对以下受体重复进行:a)接受了亚致死剂量的
照射以确定移植物排斥,或B)已接种肿瘤
细胞在BMT的时间,以分析的重要性,肿瘤坏死因子相关凋亡诱导配体通路的GVT
(and DLI)与GVHD相关。在具体目标2中,我们将研究
受体中TRAIL缺乏及其对GVHD发展的影响。
在具体目标3中,我们提出产生在以下方面具有多重缺陷的小鼠:
溶细胞途径这些小鼠将用于类似的实验,
目的1和2中所述的目的,以发现与本发明的化合物的任何冗余、协同作用或拮抗作用。
这些细胞溶解途径在GVHD、GVT和移植中的作用。最后,具体
目的4我们提出通过过表达TRAIL来增强GVT活性
(by腺病毒介导的递送)。这些研究可以提供
更好地理解TRAIL通路在(a)T
(B)BMT后的GVHD、GVT和移植,
可以立即应用于临床。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marcel R M van den Brink其他文献
A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation
- DOI:
10.1182/blood-2022-162386 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Doris M Ponce;Jonathan U Peled;Bindu Tejura;Christopher Ford;Marcel R M van den Brink;Mary Jane Lombardo;Satyajit Kosuri;Nandita Khera;Zachariah Defilipp;Lisa von Moltke - 通讯作者:
Lisa von Moltke
Microbial Changes in Response to a Plant-Based Diet and/or Supplements in SMM Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via Healthtree: The Nutrition Prevention (NUTRIVENTION-2) Study
针对 SMM 患者基于植物的饮食和/或补充剂的微生物变化:通过 Healthtree 进行的一项全国多臂随机前瞻性远程医疗研究:营养预防(NUTRIVENTION-2)研究
- DOI:
10.1182/blood-2022-160241 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:23.100
- 作者:
Francesca Castro;Nathan W. Sweeney;Andriy Derkach;Kadiatou Traore;Aishwarya Anuraj;Laura Guttentag;Jenna Blaslov;Ana Sahagun;Jay Hydren;Cynthia Chmielewski;Terry Golombick;Justin R Cross;Jun J Mao;Marcel R M van den Brink;Saad Usmani;Jennifer M. Ahlstrom;Alexander M Lesokhin;Urvi A Shah - 通讯作者:
Urvi A Shah
Marcel R M van den Brink的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marcel R M van den Brink', 18)}}的其他基金
The role of the intestinal microbiome in cancer immunotherapy
肠道微生物组在癌症免疫治疗中的作用
- 批准号:
10738072 - 财政年份:2023
- 资助金额:
$ 35.4万 - 项目类别:
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
第三方“现成的”成熟或前体 CAR T 细胞,用于预防或治疗异基因 HCT 后的恶性复发
- 批准号:
9762469 - 财政年份:2019
- 资助金额:
$ 35.4万 - 项目类别:
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
第三方“现成的”成熟或前体 CAR T 细胞,用于预防或治疗异基因 HCT 后的恶性复发
- 批准号:
10417210 - 财政年份:2019
- 资助金额:
$ 35.4万 - 项目类别:
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
第三方“现成的”成熟或前体 CAR T 细胞,用于预防或治疗异基因 HCT 后的恶性复发
- 批准号:
10179457 - 财政年份:2019
- 资助金额:
$ 35.4万 - 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
- 批准号:
10374029 - 财政年份:2018
- 资助金额:
$ 35.4万 - 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
- 批准号:
10369479 - 财政年份:2018
- 资助金额:
$ 35.4万 - 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
- 批准号:
9899952 - 财政年份:2018
- 资助金额:
$ 35.4万 - 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
- 批准号:
10524114 - 财政年份:2018
- 资助金额:
$ 35.4万 - 项目类别:
Endothelial cells regulate immune reconstitution after hematopoietic stem cell transplantation
内皮细胞调节造血干细胞移植后的免疫重建
- 批准号:
10357767 - 财政年份:2018
- 资助金额:
$ 35.4万 - 项目类别:
Project 2: Thymic and peripheral Aspects of T cell Aging and Rejuvenation
项目 2:T 细胞衰老和再生的胸腺和外周方面
- 批准号:
10226922 - 财政年份:2017
- 资助金额:
$ 35.4万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 35.4万 - 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 35.4万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 35.4万 - 项目类别:
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 35.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 35.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 35.4万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 35.4万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 35.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 35.4万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 35.4万 - 项目类别:
Discovery Grants Program - Individual